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inactivation and tumorigenesis. Several tumor virus proteins, such as SV40, the adenoviruses, and the human papillomaviruses, bind to wild-type p53 and inhibit its tumor suppressor a~tivity.~ Recently, a 90-kD protein that forms a complex with both mutant and wild-type p53 has been identified and called the mouse double minute 2 (MDM-2).'v6 The MDM-2 protein, originally identified as a product of the murine double minute 2 gene, is amplified in a transformed derivative of mouse BALB/c 3T3 cells.' The MDM-2 amino acid sequence contains two potential metalbinding motifs, an acidic domain often found in trans-activators, and a region of basic amino acid that may serve as a nuclear localization signal. ' Two observations suggest that the MDM-2 protein plays a role in cellular proliferation by suppressing the activity of the p53 protein: (1) overexpression of the MDM-2 gene in cells increases their tumorigenic potential,' and (2) binding of the MDM-2 protein to the p53 protein inhibits the p53 protein-mediated trans-activation of p53-responsive elements in the muscle creatine kinase gene.6 This hypothesis was supported by the finding that the human MDM-2 gene, which has been mapped to chromosome 12q13-14, was strikingly amplified in 17 of 47 cases of sarcoma.* In addition, a recent study suggests that MDM-2 gene amplification is associated with tumor progression and metastasis in osteo~arcoma.~ Initial studies have shown gene amplification in sarcoma and not in colonic or gastric tumors.* MDM-2 RNA as well as protein were overexpressed in sarcoma cell lines that show gene amplification.' It is presumed that MDM-2 overexpression in sarcoma leads to tumorigenesis by inactivating ~5 3 . '~ We investigated MDM-2 expression and amplification in leukemias. We used Southern blot analysis to determine MDM-2 gene amplification and multiplex reverse transcription/polymerase chain reaction (RT/PCR) to study its levels of expression. We coamplified the MDM-2 and the overexpression in some cases of leukemias was mmparable to that observed in some cases of sarcomas, which demonstrate more than 50-fold MDM-2 gene amplification. Furthermore, we divided these cases into different prognostic groups according to their karyotypic abnormalities. MDM-2 overexpression seemed to be associated with unfavorable chromosomal abnormalities. These findings suggest that the expression of the MDM-2 gene is altered in a significant fraction of human leukemias and MDM-2 may play a significant role in leukemogenesis. In addition, these results suggest that mechanisms other than gene amplification may play a significant role in deregulating the MDM-2 expression. 0 1993 by The American Society of Hematology.
@-actin mRNAs in normal and leukemic patient samples and in leukemic cell lines. ,&actin was used as an internal control.''~12 No gene amplification was detected by Southern blot analysis in any of the 48 cases of leukemia we studied. However, 34 of 64 (53%) leukemias showed significantly high levels of MDM-2 mRNA expression. MDM-2 overexpression was also detected in some leukemic cell lines (MDA/AML-8, K562, and Raji). Furthermore, in acute myeloid leukemia (AML) patients, although the number of patients was somewhat small, overexpression of MDM-2 mRNA was apparently associated with cytogenetic characteristics that typically confer an unfavorable prognosis. The overexpression of MDM-2 mRNA in these leukemias may play a role in the leukemogenic process and may account for the relatively low incidence of p53 mutations in hematopoietic malignancies. RNA was extracted by the guanidine hydrochloride method as described previously." Briefly, tissues were lysed in a highly concentrated solution ofguanidine hydrochloride in the presence of dithiothrcitol (DTT). The cell suspension was centrifuged at 3 . 0 0 rpm for 10 minutes at 4°C. and the supernatant was transferred to a 15-mL tube and precipitated overnight with 0.5 volume of l00% ethanol. The following day. the solution was centrifuged at 3.00 rpm for 30 minutes at 4°C. The pellet was resuspended again in a highly concentrated solution of guanidine hydrochloride in the presence of DTT and precipitated overnight with 0.5 volume of 100% ethanol. The suspension was centrifuged as on day 2. and the pellet was resuspended in 25 mmol/L EDTA and mixed with an equal volume of 4: I ch1oroform:isobutanoI solution. The suspension was then centrifuged for 5 minutes at l .000 rpm. and the upper layer was transferred to a 15-mL conical tube and precipitated overnight with 3X volume of 4 mol/L sodium acetate. On day 4. the sample was centrifuged and the pellet was resuspended in I mL of 80% ethanol. precipitated for I hour at -75°C. followed by centrifugation at 14.000 rpm at 4°C for 35 minutes. The RNA pellet was lyophilized and resuspended in 50 to 100 pL ofwater and stored at -75°C. DNA for Southern blot studies was extracted within 8 hours of collection as described previ~u s l y . '~ Briefly. white blood cells were lysed in 3 mL of aqueous buffer with detergent. Proteins were digested by the addition of proteinase K (Sigma Chemical CO) and incubated at 50°C for 1 hour, followed by sequential organic extraction in phenol/chloro-/?. \:. I cindDh'9 c~.~ircit*iion.
MATERIALS AND METHODS

Cell
form and chloroform. The purified DNA in the aqueous phase was prccipitated by the addition of at least 0.1 volume of 3 mol/L sodium acetate and 100T isobutanol. The DNA wasdissolved in Tris-EDTA buffer and digested with the appropriate restriction enzyme.
Sordlrcwi hloi cincilwi.s c!/ilw .l.II)Jl-?.q(~n(~. Southern blot analysis was performed as previously described." Ten micrograms of digested DNA was loaded into an 0.7% agarose gel containingethidium bromide. Electrophoresis was performed at 22 V. The electrophoresed DNA was transferred to a nylon membrane by the vacuum transfer technique at 6 to 8 mm Hg for 90 minutes. Next. the membrane was dried in an 80°C oven for 30 minutes and prehybridized in 20 mL of standard prehybridimtion solution for 2 hours. MDM-2 probe was radioactively labeled to high specific activity by the random primer method (Bethesda Research Laboratories Life Technologies, Inc. Gaithersburg. MD). The final probe concentration was 2 to 2.5 X 1O6dpm/mL in the hybridization mix. We used a I .4-kb fragment ofthe MDM-2 cDNA. which represents almost the entire coding sequence. as a probe. Following hybridization the filters were exposed to Kodak AR film (Eastman Kodak. Oligonucleotides were synthesized using a DNA synthesizer from Applied Biosystems (Foster City. CA). Oligonucleotides were fully deprotected after synthesis and purified using high-pressure liquid chromatography. Samples were amplified through 30 consecutive cycles. Each amplification cycle consisted ofa denaturation step at 94°C for I minute, primer annealing at 57°C for I minute. and extension at 74°C for 4 minutes. Cycles were preceded by incubation for 5 minutesat 95°C to ensure full denaturation ofthe target DNA. and were followed by an extra 7 minutes of incubation at 74°C after the final cycle to ensure full extension of product. The PCR reactions were performed on a DNA thermal cycler (Perkin Elmer-Cetus Instruments. Nonvalk. CT). The amplified fragment of MDM-2 was 335 bp, and the 8-actin-amplified fragment was approximately 240 bp.
In all cases the completed reacAna/y.yi.s qfamp/i,l!'hed samples. tions were resolved by electrophoresing a I O " aliquot of each amplification reaction on a gel containing 8% polyacrylamide and 8 mol/L urea. The gel was then transferred to Whatman 3M paper (Schleicher and Schuell, Inc. Keene, NH), covered with Saran wrap (Reynolds Corp, Richmond, VA), and exposed to Kodak AR film at -70°C. The relative density of the amplification product bands was counted using a 603 Betascope phosphor image analyzer.
For restriction enzyme analysis of the PCR product, the amplified cDNA was extracted with phenol/chloroform and precipitated with ethanol before restriction enzyme digestion. Restriction enzyme digestion ofthe amplified cDNA was performed with Hind111
and Rsa I (New England Biolabs, Beverly, MA), according to the manufacturer's suggested conditions. RNA was separated by electrophoresis in a MOPS-formaldehyde gel and transferred to nylon filter. Transfer and hybridization were performed as described previo~s l y . *~ RNA was hybridized to the same MDM-2 probe that was used for Southern blot analysis. The same blot was stripped and hybridized to 0-actin probe encompassing 240 bp of the @-actin cDNA isolated from RT/PCR using the same @-actin primers that were used in the coamplification ofthe MDM-2 and the &actin (see above).
Norfhem hlor ono/j3sis.
RESULTS
Lack of MDM-2 gene amplification in leukemia. Using
Southern blot analysis, we analyzed 48 cases of leukemia and three cases of reactive lymphocytosis for MDM-2 gene amplification (Fig 1) . No significant gene amplification was detected in any of the 5 I cases examined. This includes 22 cases of chronic lymphocytic leukemia (CLL), 3 cases of hairy cell leukemia (HCL), 6 cases of acute lymphoblastic leukemia (ALL), 15 cases of AML, 2 cases of myelodysplastic syndrome (MDS), and 3 cases of reactive lymphocytosis.
The copy number of the MDM-2 gene was compared with immunoglobulin copy number. In some cases of CLL, the signals of the MDM-2 probe, when compared with those of the JH probe, showed a minor increase consistent with trisomy 12, which isa relatively common chromosomal abnormality in CLL." One case of CLL showed rearrangement in MDM-2 after digestion with Hind111 ( Fig IA) and Pvu I1
(not shown). Chromosomal studies of this case showed no visible chromosome I2 abnormality, but other clonal chromosomal abnormalities were observed, including 45, X, -Y, t(9q;l8p). This case showed MDM-2 mRNA overexpressed, and further analysis of this case is in progress.
The MDM-2 mRNA is ovcre.pressed in leukemias. The relative level of MDM-2 mRNA in various leukemic samples was established by RT/PCR and coamplification of the MDM-2 and the &actin mRNAs. We first synthesized MDM-2 and &actin cDNAs by RT using 3' antisense The level of MDM-2 overexpression is indicated by one plus sign (+) for low. two (++) for moderate, and three (+++)for high overexpression in relation to @-actin.
primers. Then we used two sets of primers specific for each ofthe mRNAs (Fig 2) to amplify the @-actin and the MDM-2 cDNAs. The 5' primers in each reaction were '*P end-labeled to increase sensitivity and allow direct visualization after electrophoresis on a denaturing polyacrylamide gel. The @-actin and MDM-2 5' primers were end-labeled at the same time to the same specific activity. Previous studies by us" and other investigators" demonstrated that the relative ratios of the amplification products using this multiplex RT/PCR accurately reflect the relative ratio of input mRNAs. The relative ratio of MDM-2:P-actin was quantified using a Betagen phosphor imager. Because @-actin amplification efficiency is not necessarily similar to that of MDM-2, this assay was used only to compare the relative ratio of MDM-2 and @-actin between various samples and normal tissues.
To verify the identity of MDM-2 amplification products. we digested the amplification products with Hind111 and Rsal restriction enzymes (Fig 2) . Because the amplification products were 5' end-labeled, only one fragment was visualized. The size of the amplification products and the subsequent restriction confirmed the specificity of the technique. The MDM-2 amplification product contains the expected Hind111 and Rsa I sites at the appropriate size. In addition, the level of MDM-2 mRNA expression by RT/PCR was confirmed in a few patients by Northern analysis (Fig 3) . We were able to obtain adequate RNA for Northem analysis from five patients, two normal and three overexpressors, all of which showed complete agreement with the RT/PCR results (Fig 3) . Northern blots were probed first with MDM-2 and then with @-actin probe. Using this multiplex RT/PCR assay, we analyzed MDM-2 expression as compared with the @-actin in several normal tissues including peripheral blood, bone marrow, soft tissue, epithelial tissue, kidney. and liver. All normal tissues showed a low level of MDM-2 mRNA expression. The MDM-2 amplification products of most normal samples were less than 10% of the @-actin amplification products, and none of them was more than 16%. We considered a ratio of MDM-2:b-actin of 20% to 40% as a small increase (+), 41% to 80% as a moderate increase (++), and greater than 80% as a high increase (+++). We analyzed the level of MDM-2 expression in several cell lines (see Materials and Methods), only MDA/AML-8. K562. and Raji cell lines showed significant levels of MDM-2 mRNA overexpression (Fig 4) . Table I and Figs 4 and 5 summarize our findings in various types of leukemias. Fifty-three percent of all leukemic samples showed overexpression of the MDM-2. In CLL, there were low levels of overexpression in 73% of the cases, whereas no overexpression was detected in two cases of HCL. Most of these CLL cases were in advanced stages (Binet clas~ification)~~ (seven patients stage C. two patients stage A. and three unknown). Fifty-three percent of AML cases showed overexpression of MDM-2 mRNA. Interestingly, no overexpression was detected in any of the four cases of CML or any of the four cases of the acute progranulocytic leukemia (Table 2) .
with unfavorable clirotnosomal change.% When we divided the AML cases into three prognostic groups according to their chromosomal abnormalities. favorable, unfavorable. and standard24 (Table 3) . we found that overexpression of MDM-2 was more closely associated with the unfavorable prognostic group. Favorable chromosomal changes include AML cases with chromosomal abnormalities such as t(8:2 I), t( 15: I7), inv ( 1 6). and t(9: 1 I). The unfavorable group included -5, -7, +8, and other complex karyotypes. The standard risk group included patients with normal karyotype. Interestingly, 50% of the standard prognostic group demonstrated overexpression of MDM-2 mRNA.
Work is in progress to evaluate whether MDM-2 overexpression in this group has any prognostic value.
Relativelv high level of MDIM-2 mRNA is expressed in leukemias. To evaluate the relative abundance of the MDM-2 mRNA, we compared the relative expression of MDM-2 mRNA in these leukemic samples with that of saruse only. coma samples that show a high level of gene amplification (Fig 6) . MDM-2 mRNA expression in some cases of sarcoma that showed striking 50-to 100-fold gene amplification was not that different from the level of expression in some cases of leukemias.
DISCUSSION
Mutational inactivation of p53, a tumor suppressor gene. is relatively infrequent in hematologic neoplasm^.'^-^' However. intragenic mutation of p53 is not the only mechanism by which this gene is inactivated. Abnormalities in other cellular proteins that interact with the p53 protein and coregulate its function may play a significant role in its inactivation and in the progression of the neoplastic pro~ess.'.~.~ In contrast with viral oncoproteins. little is known about the cellular co-regulators of p53. Recent reports suggest that the MDM-2 oncoprotein is one of these cellular co-regulators.'.' MDM-2 forms a complex with the mutant and wildtype p53 protein and suppresses its /runs-activation function! The MDM-2 gene is amplified and overexpressed in a significant number of sarcomas. which suggests that it plays a role in the tumorigenic process of We examined leukemic samples for gene amplification. All 48 cases that we examined showed no evidence of gene amplification (Fig I) . We investigated the levels of MDM-2 mRNA expression in various types of leukemias. We used the highly sensitive RT/PCR technique and co-amplified the MDM-2 and p-actin mRNAs. The use of a PCR-based technique enabled us to analyze small fragments of tissue. @-actin, used as an internal control. allowed us to compare the level of MDM-2 mRNA expression between various 
@-&Actin
samples. The specificity of the amplification products was confirmed by restriction enzyme analysis of the amplification products (Fig 2) . The quantitative accuracy of the coamplification was confirmed by Northern analysis (Fig 3) . In addition, previous work by us".'' and other investigators" has demonstrated that the relative ratio ofthe amplification products using this coamplification technique reflects the exact relative ratio of the mRNAs.
Using RT/PCR, we detected MDM-2 mRNA overexpression in a significant number (34 of 64, 53%) of acute leukemias. As shown in Table I . MDM-2 overexpression was detected in 9 of I2 cases of CLL (75%). I7 of 32 cases of AML (53%). 3 of 7 cases of ALL (42%), and 5 of 7 cases of MDS (71%). A few cases of chronic myeloid leukemia (CML) (four cases) and HCL (two cases) that we analyzed showed no evidence of MDM-2 overexpression. Table 2 shows the MDM-2 expression profile in AML and MDS cases as subclassified according to the French. American. and British cla~sification.~~.~~ Interestingly, none of the four cases of APL showed overexpression of MDM-2 mRNA.
To evaluate whether MDM-2 overexpression has any prognostic value, we subdivided the AML cases according to three cytogenetic prognostic groups: favorable. unfavorable, and standard.24 Apparently, overexpression was associated with unfavorable chromosomal abnormalities (Table  3) . Of interest. we found that 50% of the standard group showed overexpression. Further follow-up of these patients may help us determine whether MDM-2 overexpression in this group may confer a different prognosis. The number of our AML cases was relatively small, and further studies are necessary to confirm the prognostic value of MDM-2 overexpression in various types of leukemias. In addition, we use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From must point out that most of our CLL patients had advanced-stage disease; therefore, the high frequency of overexpression (73%) in these patients may reflect more aggressive disease.
To examine the level of MDM-2 overexpression, we compared the level of MDM-2 mRNA in some leukemia samples with that in samples of sarcomas that showed significant MDM-2 gene amplification. To our surprise the level of MDM-2 expression in some leukemia samples was comparable to that in some samples of sarcomas that show 50-fold MDM-2 gene amplification. Because we did not detect gene amplification in leukemias, the mechanisms of MDM-2 overexpression in this group of tumors seems to be caused by alteration in either cis-or trans-acting factors that regulate MDM-2 expression.
In summary, we demonstrate that the MDM-2 oncoprotein is deregulated in leukemias and mechanisms other than gene amplification are responsible for this overexpression. In addition, our data suggest that MDM-2 overexpression may indicate more aggressive disease. The demonstration by Finlay' that MDM-2 protein can overcome the growth suppressive activity of p53 may explain the relatively low incidence of p5 3 mutation in hematologic neoplasms. However, because MDM-2 forms a complex with the mutant p53 in addition to the wild-type, it is possible that MDM-2 propagates the altered function of the mutated p53 protein, thus contributing to the tumorigenic process. Further studies to explore the basis for this overexpression may shed some light on the steps involved in the leukemogenic process.
